Related Experiment Video

Updated: Mar 15, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.8K

Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials

Melanie Hemmrich, Eric D Peterson, Karen Thomitzek

  • 1Jeffrey Weitz, Thrombosis & Atherosclerosis Research Institute, 237 Barton Street East, C5-123, Hamilton, ON L8L 2X2, Canada, Tel.: +1 905 574 8550,

Thrombosis and Haemostasis
|September 15, 2016
PubMed

Insights

Atrial fibrillation increases stroke risk. New studies explore rivaroxaban for stroke prevention in specific patient groups, aiming for safer and more effective anticoagulation strategies.

Area of Science:

  • Cardiology and Thrombosis
  • Pharmacology
  • Clinical Trials

Background:

  • Atrial fibrillation (AF) significantly elevates ischemic stroke risk.
  • Anticoagulants, particularly non-vitamin K antagonist oral anticoagulants (NOACs), are preferred over antiplatelet agents for stroke prevention in non-valvular AF (NVAF).
  • Challenges persist in managing stroke risk in specific NVAF patient subsets due to limited data and complex treatment needs.

Purpose of the Study:

  • To investigate the efficacy and safety of rivaroxaban in stroke prevention across diverse patient populations with unmet clinical needs.
  • To evaluate rivaroxaban's role in scenarios with sparse anticoagulant data, including post-transcatheter aortic valve replacement and embolic stroke of undetermined source.
  • To assess rivaroxaban-based strategies compared to standard antiplatelet or vitamin K antagonist regimens.

Main Methods:

  • Focus on three key randomized controlled trials (RCTs): PIONEER AF-PCI, NAVIGATE ESUS, and GALILEO.
  • These trials investigate rivaroxaban, a direct oral factor Xa inhibitor, in specific patient groups.
  • Utilizing open-label and comparative designs to gather data on rivaroxaban's utility in novel settings.

Main Results:

  • Data from these trials aim to expand the evidence base for rivaroxaban beyond established indications.
  • Results will inform treatment strategies for patients requiring anticoagulation alongside antiplatelet therapy or in specific stroke etiologies.
  • The studies contribute to understanding rivaroxaban's safety and effectiveness in broader patient cohorts.

Conclusions:

  • These ongoing trials are crucial for optimizing stroke prevention strategies in a wider range of patients with AF and related conditions.
  • Findings will support the use of rivaroxaban in complex clinical scenarios, potentially improving patient outcomes.
  • The research addresses the need for evidence-based treatment options for high-risk patient groups.

Keywords:
Stroke preventionatrial fibrillationpercutaneous coronary interventionrivaroxabantranscatheter aortic valve replacement

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
794
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
369
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
580
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
528
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
494